Instruction 1(b).

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
houre per recognese:	0.5								

C Deletionship of Deporting December (a) to Jacus

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person  Chodakewitz Jeffrey  (Last) (First) (Middle)  C/O VERTEX PHARMACEUTICALS INCORPORATED  50 NORTHERN AVENUE					$ \mathbf{V} $	VERTEX PHARMACEUTICALS INC / MA [ VRTX ]  3. Date of Earliest Transaction (Month/Day/Year) 11/18/2015								eck all appli Directo	Autoriship of Reporting k all applicable)  Director  Officer (give title below)		10% Ov Other (s below)	ner
															EVP GMDA, CMO			
					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)													- 1	,	iled by One	e Repo	orting Perso	n
BOSTO	N M	[A	02210		_									Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)															
		Tab	le I - No	n-Deri	vativ	e Se	curit	ties Ac	quired,	Dis	posed o	of, or Be	neficial	ly Owned				
			Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)						es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock 11/18/					8/201	2015		М		10,31	5 A	\$73.5	1 110	110,877		D		
Common Stock 11/18/				8/201	/2015		S <sup>(1)</sup>		10,31	5 D	\$130	100	100,562		D			
		-	Table II -								osed of, converti			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)		e	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$73.51	11/18/2015			M			10,315	(2)	(	01/01/2024	Common Stock	10,315	\$0.00	30,93	8	D	

## **Explanation of Responses:**

- 1. Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
- 2. The option vests in 16 quarterly installments from 01/02/2014.

## Remarks:

Omar White, Attorney-In-Fact 11/20/2015

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.